Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

863
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
863
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

366
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
366
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

739
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
739
Autoimmune Disorders01:29

Autoimmune Disorders

2.3K
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
2.3K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

683
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
683
T Cell Types and Functions01:24

T Cell Types and Functions

3.2K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comprehensive Evaluation of Coextraction Workflows for Enhanced Multiomics Integration in Complex Biological Samples.

Journal of proteome research·2026
Same author

A Unified Viscoelastic Solver for Multiphase Fluid Simulation Based on a Mixture Model.

IEEE transactions on visualization and computer graphics·2026
Same author

Cross-robot behavior adaptation through intention alignment.

Science robotics·2026
Same author

Head-to-head comparison of the ability of the cardiometabolic index and triglyceride-glucose index to predict 3-year major adverse cardiovascular events in patients with atrial fibrillation: insights from a community cohort.

Lipids in health and disease·2026
Same author

Cardiometabolic index as a predictor of major adverse cardiovascular events in atrial fibrillation: insights from a community-based cohort.

Frontiers in endocrinology·2025
Same author

<i>Letter:</i> Mild Traumatic Brain Injury in Older Adults: Recovery Course and Insights on Early Predictors of Outcome.

Journal of neurotrauma·2025
Same journal

Comparative Phytochemical Characterization and Antibacterial Activity of Ethanol and Aqueous Extracts of Moringa peregrina and Moringa oleifera against Multidrug-Resistant Bacteria.

Current pharmaceutical biotechnology·2026
Same journal

Unveiling Aptamers for Targeted Tumour Therapies and Detection: Systematic Evolution of Ligands by Exponential Enrichment (SELEX) Technology in Oncology.

Current pharmaceutical biotechnology·2026
Same journal

Nanosuspensions-Based Dry Powder Inhalers for Pulmonary Delivery of Hydrophobic Natural Products: Formulation Strategies, Efficacy, and Challenges.

Current pharmaceutical biotechnology·2026
Same journal

Bone Marrow Mesenchymal Stem Cell-Derived Exosomes Accelerate Diabetic Rat Wound Healing by Inhibiting Pyroptosis through the NLRP3/Caspase-1/GSDMD Pathway.

Current pharmaceutical biotechnology·2026
Same journal

Cyperotundone Regulates Polo-like Kinase 1-mediated Glycolysis to Inhibit the Proliferation of Breast Cancer Cells.

Current pharmaceutical biotechnology·2026
Same journal

Risk Factor Analysis and Nomogram for Predicting 28-day in-hospital Mortality in ICU Patients with Liver Necrosis.

Current pharmaceutical biotechnology·2026
See all related articles

Related Experiment Video

Updated: Apr 24, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

22.1K

Biologics in systemic sclerosis.

Jingxiu Xuan, Long Shen, Chongjie Zhang

  • 1Department of Medicinal Immunology, West China School of Preclinical and Forensic Medicine, Sichuan University, Address: 17 Renming Street South, 3rd Section, Chengdu, Sichuan, China 610041. cjzhang49@hotmail.com.

Current Pharmaceutical Biotechnology
|September 13, 2014
PubMed
Summary
This summary is machine-generated.

Systemic sclerosis (SSc) is an autoimmune disease causing organ hardening. This review explores key mediators involved in SSc pathogenesis, highlighting potential new therapeutic targets for this condition.

More Related Videos

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice
08:09

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice

Published on: March 24, 2017

7.3K

Related Experiment Videos

Last Updated: Apr 24, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

22.1K
Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice
08:09

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice

Published on: March 24, 2017

7.3K

Area of Science:

  • Autoimmune diseases
  • Rheumatology
  • Immunology

Background:

  • Systemic sclerosis (SSc), or scleroderma, is a complex autoimmune condition.
  • It is defined by excessive collagen production, leading to organ hardening and pulmonary arterial hypertension.
  • SSc presents significant morbidity and mortality, with uncertain pathogenesis and limited effective treatments.

Purpose of the Study:

  • To review the role of key mediators in Systemic Sclerosis pathogenesis.
  • To identify potential therapeutic targets based on emerging understanding of SSc.
  • To summarize the effects of these mediators within the context of SSc.

Main Methods:

  • Literature review of scientific publications.
  • Analysis of key mediators implicated in SSc.
  • Synthesis of current understanding of SSc pathogenesis.

Main Results:

  • Identified several key mediators contributing to SSc.
  • Described the specific effects of these mediators in disease development.
  • Highlighted the potential for targeting these mediators in future therapies.

Conclusions:

  • Understanding key mediators is crucial for developing effective SSc therapies.
  • Targeting specific mediators offers a promising avenue for SSc treatment innovation.
  • Further research into these mediators may lead to improved patient outcomes.